Pain during copamer injection in Multiple Sclerosis disease. Multiple sclerosis
Conditions
Interventions
Intervention 1: Topical administration of clove extract (clove) as a topical gel made by Ahura Darou Shiraz Company with the active ingredient eugenol and containing 20% of clove oil (essential oil of
Sponsors
Sanandaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Age: 18-40 years old BMI: 19- 25 No diabetic neuropathy based on the history and diagnosis of the treating physician Full consciousness and the ability to analyze the amount of pain Absence of scars and lesions at the injection site Do not receive meperidine 4 hours and morphine 5 hours before intervention Use of Copamer(Glatiramer Acetate) injection medication in patients with MS
Exclusion criteria
Exclusion criteria: Patient's sensitivity to clove extract Coagulation problem Need subcutaneous injection of another medication in the area of copamer injection Chronic pain at the site of copamer injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score in injection site after Copamer administration. Timepoint: Immediately after injection. Method of measurement: Visual Analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamira Vash
Sanandaj University of Medical Sciences
Outcome results
None listed